NeuroBo Pharmaceuticals Advances Clinical Trials for Metabolic Disease Therapies
NeuroBo Pharmaceuticals, Inc. is at the vanguard of developing innovative therapies for metabolic diseases. With two leading programs, DA-1241 and DA-1726, spearheading its research and development initiatives. These programs are designed to address conditions that have a significant impact on global health, such as metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes (T2D), as well as obesity.
DA-1241, a novel therapeutic candidate, is targeting the complex challenges of MASH and T2D. As a G-Protein-Coupled Receptor 119 (GPR119) agonist, it has demonstrated potential in preclinical studies to inhibit lipid synthesis and activate cells that play a pivotal role in the pathogenesis of MASH. Moreover, it has shown promise in stimulating insulin secretion and the release of metabolic peptides that are essential for the regulation of glucose and lipid metabolism. The company is currently conducting a two-part Phase 2a clinical trial to evaluate the efficacy of DA-1241 in patients with suspected MASH and confirmed pre-diabetes or T2D. The healthcare community is anticipating the results, which are expected in the latter half of 2024.
In the battle against obesity, the company’s DA-1726, an oxyntomodulin (OXM) analogue, functions as a dual agonist for the GLP-1 receptor and the glucagon receptor. This compound has outperformed existing medications in preclinical studies, showcasing superior weight loss effects. Given the increasing prevalence of obesity both in the United States and worldwide, the implications of the company’s research into DA-1726 could be profound for public health. Following the submission of an Investigational New Drug (IND) application, the company is preparing to commence a Phase 1 clinical trial in early 2024.
The company’s dedication to combating metabolic diseases is further evidenced by its strategic partnership with Dong-A ST Co. Ltd. a prominent pharmaceutical company in South Korea. In September 2022, the company entered into an exclusive license agreement with Dong-A ST for the rights to DA-1241 and DA-1726, highlighting a mutual commitment to advancing healthcare solutions.
Patient recruitment for the Phase 2 clinical trial of DA-1241 is currently underway, and preparations for the Phase 1 trial of DA-1726 are advancing. These clinical trials are critical steps in the company’s mission to introduce novel treatments to the market.
NeuroBo Pharmaceuticals is making significant progress in the fight against metabolic diseases with its advanced clinical trials. The company’s research endeavors could lead to groundbreaking treatments for MASH, T2D, and obesity, which collectively affect millions of individuals across the globe. With the backing of its strategic partner, Dong-A ST, the company remains steadfast in its pursuit of enhancing patient outcomes. As NeuroBo moves forward with its clinical trials, the outcomes are highly anticipated by the healthcare community and could potentially reshape the landscape of metabolic disease therapy.
Source link
